Advertisement

Topics

Latest "BIO RELIANCE" News Stories

13:50 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "BIO RELIANCE" found in our extensive news archives from over 250 global news sources.

More Information about BIO RELIANCE on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BIO RELIANCE for you to read. Along with our medical data and news we also list BIO RELIANCE Clinical Trials, which are updated daily. BioPortfolio also has a large database of BIO RELIANCE Companies for you to search.

Showing "RELIANCE" News Articles 1–25 of 613

Friday 21st September 2018

argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

Regulated information September 21, 2018, 4:00 PM ET - 10:00 PM CEST Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its public offering in the United ...


GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% redu...

Thursday 20th September 2018

Covalon to Host Conference Call to Discuss Definitive Agreement to Acquire AquaGuard

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has scheduled a conference call for Friday September 21st 2018 at 9:00am EST. The conference call is being held to discuss the announcement of Covalon’s definitive agreement to acquire AquaGuard, the Seattle, ...


Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor in develop...

TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that AnnoveraTM (segesterone acetate and ethinyl estradiol vaginal system) has been granted marketing exclusivity as a new chemical entity (NCE) from the U.S. Food and Drug Administration. The five-year NCE exclusivity runs for five years from th...

Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it will be presenting at the Fourth Annual Robins Equity Research Roundup, held September 25 – 26, 2018 near Portland, Oregon. The Equity Research Roundup is sponsored by...

Wednesday 19th September 2018

Biofrontera AG: Biofrontera to present at the Baader Investment Conference

DGAP-News: Biofrontera AG / Key word(s): Conference 19.09.2018 / 09:28 The issuer is solely responsible for the content of this announcement. Biofrontera to present at the Baader Investment Conference Leverkusen, Germany, September 19, 2018 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be participating a...

Tuesday 18th September 2018

argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering

Regulated information - Inside information  September 18, 2018, 8:45 PM ET - September 19, 2018, 2:45 AM CEST Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pr...

Reliance on inpatient BP readings may cause overtreatment

About 14 percent of older adults hospitalized for common, non-cardiac conditions were discharged with more intensive blood pressure medication, according to an analysis published in The BMJ. The concerning part: More than half of those patients actually demonstrated good blood pressure (BP) control in an outpatient setting, suggesting overtreatment from hospital physicians.

SPIRIT DSP: MTS and MEDSI Launched VideoMost Software-Powered Mobile Telemedicine Services

SPIRIT DSP, business communications software engines provider, with software products serving more than 1 billion people in 100+ countries, announced that MEDSI, Russia's largest private national healthcare chain, and MTS, the country’s biggest mobile operator, have launched SmartMed, a telemedicine platform offering digital medical services. Th...

20182023 China Capecitabine Market Report Status and Outlook [Report Updated: 13032018] Prices from USD $3360

In 2017, the Capecitabine market size was xx million USD in China, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In China market, the top players include Roche Teva Mylan Hikma Hengrui Medicine Cipla Reliance Group HeteroSplit by product types/category, covering 500 mg 150 mgSplit by applications/end use industries, covers Breast C...

Visioneering Announces First International Revenues and Attendance at Myopia Conference in Australia

Recently Signed Australian Optometrists Report Rapid Patient Success With NaturalVue® Multifocal 1 Day Contact Lenses Normally, one could expect a lag between accounts signing up and revenue starting from those accounts, but shortly after signing Visioneering Technologies’, Inc. (ASX: VTI) first international eye care practitioners in Australia, the...

Monday 17th September 2018

MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Alliance 17.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Martinsried/Munich, Germany, and Ballerup, Denmark, September 17, 2018   MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics   LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG...

Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today acceptance into the National Institutes of Health (“NIH”) Commercialization Accelerator Program (“CAP”) 2018-2019. The Company was sel...

Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today closing of a $3 million private placement. The Company entered into a definitive securities purchase agreement with an existing investor, John K. Scott, ...

NHI Announces $300 Million Five-Year Term Loan

National Health Investors, Inc. (NYSE: NHI) announced today it has entered into a $300 million bank term loan with a five-year maturity. At closing, proceeds from the new term loan were used to reduce the outstanding balance on NHI’s $550 million revolving credit facility and to increase NHI’s available liquidity for making new investments. The terms o...

Friday 14th September 2018

Covalon to Showcase IV Clear at AVA Scientific Meeting 2018

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV.V; OTCQX: CVALF), an advanced medical technologies company, today announces that it will be showcasing IV Clear at the 2018 Scientific Meeting for the Association for Vascular Access (“AVA” or the “Meeting”). Covalon’s IV Clear™ is indicated to cover and pro...

Thursday 13th September 2018

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel...

MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106 (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 13.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Mechelen, Belgium, September 13, 2018   MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106   MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galap...

STAAR Surgical Announces Approval by the FDA of the Visian Toric ICL for the Correction of Myopia with Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that the FDA has granted approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia with astigmatism. This approval represents a meaningful expansion o...

Co-Diagnostics Adds Central and South America to its List of International Target Markets

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it is expanding its list of international target markets with the completion of a trip to interested laboratories and potential future sales installations across Central America. As...

MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study results/Conference 13.09.2018 / 10:16 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, September 13, 2018 MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis MorphoSys AG (FS...

Wednesday 12th September 2018

Galapagos raises $300 million gross proceeds in a U.S. public offering

Mechelen, Belgium, 13 September 2018, 03.00 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares ("ADSs") at $116.50 per ADS, before underwriting discounts. In addition, Galapagos has granted ...

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement wi...

MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Alliance 12.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany and Mechelen, Belgien, September 12, 2018   MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner   MorphoSys AG (FSE: MOR; Prime Standard Segment, Te...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks